Drug Trial Radar · NCT01564095
TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion
Last checked: Nov 20, 2026Latest source record: Mar 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
25
Actual
Start
Oct 2011
Primary completion
Jul 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- Ludwig-Maximilians - University of MunichAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Utilisation of extended criteria donors due to critical organ shortage contributes to increased ischemia reperfusion injury as well as mortality following liver transplantation. Experimental data show protective effects on hepatic ischemia reperfusion injury (IRI) using the calcineurin inhibitor Tacrolimus applied intravenously or directly as a hepatic rinse. Moreover clinical data indicate a protective role of a Tacrolimus rinse in human liver transplantation when using normal, healthy grafts. The effects of Tacrolimus on hepatic injury in extended donor criteria (EDC) liver grafts remain unclear. Therefore, the aim of the present study is to examine the effects of a Tacrolimus ex vivo rinse (20 ng/ml) on cellular injury after transplantation of marginal liver grafts exhibiting 2 or more EDCs according to Eurotransplant's definition of EDC grafts.
Conditions
- Terminal Liver Disease
- Ischemia Reperfusion Injury
- Graft Dysfunction
- Graft Failure
- Poor Graft Quality
Interventions
TacrolimusDrug
Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
HTK/PlaceboDrug
Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum serum ALT-levelTime frame: 48 hrs following liver transplantation
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Department of General, Visceral and Transplantation Surgery, Charité Campus Virchow-Klinikum
Berlin, Germany
Department of General and Visceral Surgery, Johann Wolfgang Goethe-University
Frankfurt am Main, Germany
Department of General, Visceral and Transplantation Surgery, Ruprecht Karls University
Heidelberg, Germany
Department of Transplantation Surgery, Johannes Gutenberg University
Mainz, Germany
Ludwig-Maximilians University, Campus Grosshadern, Department of Surgery
Munich, Germany
Department of Surgery, University of Regensburg
Regensburg, Germany
Department of General, Visceral and Transplantation Surgery, Eberhard Karls University
Tübingen, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.